Rigel Pharmaceuticals (RIGL) Payables (2010 - 2026)
Rigel Pharmaceuticals (RIGL) posted quarterly Payables of $4.5 million for Q1 2026, up 13.45% year-over-year from $4.0 million in Q1 2025, and down 37.62% quarter-over-quarter from $7.2 million in Q4 2025.
Rigel Pharmaceuticals (RIGL) Payables (2010 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Payables history runs 17 years deep, the most recent figure standing at $4.5 million for Q1 2026.
- In Q1 2026, Payables rose 13.45% year-over-year to $4.5 million; the TTM figure through Mar 2026 stood at $4.5 million (up 13.45% YoY), while the FY2025 annual figure was $7.2 million, up 115.36% from the prior year.
- Payables for Q1 2026 stood at $4.5 million, down from $7.2 million in the prior quarter.
- The five-year high for Payables was $15.0 million in Q4 2022, with the low at $2.2 million in Q2 2022.
- The 5-year median for Payables is $5.2 million (2023), against an average of $5.9 million.
- The sharpest annual moves came in 2022 and 2025: Payables soared 295.26% in 2022, then tumbled 57.37% in 2025.
- Rigel Pharmaceuticals' Payables stood at $15.0 million in 2022, then slumped by 52.39% to $7.1 million in 2023, then slumped by 53.25% to $3.3 million in 2024, then surged by 115.36% to $7.2 million in 2025, then sank by 37.62% to $4.5 million in 2026.
- Business Quant data shows RIGL's Payables at $4.5 million in Q1 2026, $7.2 million in Q4 2025, and $3.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Rigel Pharmaceuticals | 795.39 Mn | 700.06 Mn | 70.18 Mn | 4.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.01 Mn |
| Mar 31, 2026 | 4.49 Mn |
| Dec 31, 2025 | 7.19 Mn |
| Sep 30, 2025 | 3.85 Mn |
| Jun 30, 2025 | 7.29 Mn |
| Mar 31, 2025 | 3.95 Mn |
| Dec 31, 2024 | 3.34 Mn |
| Sep 30, 2024 | 3.82 Mn |
| Jun 30, 2024 | 6.13 Mn |
| Mar 31, 2024 | 9.28 Mn |
| Dec 31, 2023 | 7.14 Mn |
| Sep 30, 2023 | 8.00 Mn |
| Jun 30, 2023 | 5.24 Mn |
| Mar 31, 2023 | 6.30 Mn |
| Dec 31, 2022 | 15.00 Mn |
| Sep 30, 2022 | 2.72 Mn |
| Jun 30, 2022 | 2.16 Mn |
| Mar 31, 2022 | 4.61 Mn |
| Dec 31, 2021 | 3.80 Mn |
| Sep 30, 2021 | 3.14 Mn |